Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: cav who wrote (994)	7/9/1998 4:06:00 PM
From: BMcV	of 10280

I agree that for those of us who are holding long-term to see how the SEPR story plays out the short-term movements are just noise. They may be unimportant in the grand scheme but they are interesting. And for traders they are vital. And traders include all of us who use options, short-term trades, and margin debt to augment returns from our capital. I am in long-term, but the short-term movements help or hurt me too. Short-term, something seems to be affecting the price right at the bond conversion level. Does it matter in the big picture? No. Long-term, market acceptance may prove a tougher obstacle than FDA approval, since these aren't novel compounds, and potential benefits will be harder to prove, and sell, as we have already seen in the case of r-ketoprofen, which Bayer passed on in late '95. If Dan Root's feeling are widespread in the respiratory medical community, levalbuterol may also grow slowly unless the new study shows clearly that albuterol causes problems in long-term patients. That is my greatest worry with SEPR, that we wind up with a portfolio of products with only marginal benefits and no real marketing edge. I agree with you that is where the battle will be won or lost.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next